• Microsoft Applies AI to Digitial Cancer Pathology Imaging, World’s First Next-Generation Single-Molecule Protein Sequencing Platform, More

    Jan 26 | Bio-IT World | A Salmonella-based bactofection platform to deliver RNA payloads to treat cancer patients; tRNA therapeutics capable of overcoming genetic errors to treat genetic diseases and cancer; the Jackson Laboratory enters an expansive and exclusive intellectual property licensing agreement across six areas of human health; and more. More
  • How Recursion Hopes to Harness the Big Picture View to Understand Biology’s Landscape

    Jan 24 | Bio-IT World | In the latest episode of Trends from the Trenches podcast, host Stan Gloss of BioTeam sits down with Chris Gibson, co-founder and CEO of Recursion, to talk about Recursion’s mission to decode biology, radically improve lives, and set big goals to innovate across every stage of drug discovery. More
  • Follow the Money: University of Chicago Funds Biotech Accelerator, Breakthrough Tankless Inhaled Nitric Oxide Delivery System, More

    Jan 24 | Bio-IT World | Funding for new therapeutic targets for a proprietary genetic medicines pipeline fueled by an automated discovery engine and versatile gene-editing toolbox, an in vivo engineered cell therapy platform for immuno-oncology genomic medicines, advanced therapeutic nucleic acids manufacturing, and more. More
  • NVIDIA Highlights AI, Large Language Model Advances in Life Sciences

    Jan 20 | Bio-IT World | NVIDIA is the only semiconductor manufacturer to ever present at the J.P. Morgan Healthcare Conference, said Harlan Sur, the firm’s semiconductor analyst in his introduction of Kimberly Powell, NVIDIA’s VP of healthcare. This year—NVIDIA’s fourth year presenting at the conference—Powell emphasized why NVIDIA is a crucial part of the healthcare ecosystem. More
  • Digestion Speed The Latest Clue In Quest Against Obesity

    Jan 19 | Bio-IT World | The time it takes food to travel from the mouth to the rectum may change the metabolism of microbes in the gut. That’s one of the intriguing possibilities raised by a stool energy density study on overweight Danes recently completed by researchers at the University of Copenhagen, reports Henrik Roager, associate professor in the department of nutrition, exercise and sports. More
  • Global Federated Machine Learning Model Detects Glioblastoma Borders

    Jan 17 | Bio-IT World | In a paper published late last year in Nature Communications, researchers from Penn Medicine and Intel Labs report on what they call the largest to-date global federated learning effort to develop an accurate and generalizable machine learning model for detecting glioblastoma borders. The work has important implications both clinically and as a model for future large, federated learning projects. More
  • At J.P. Morgan, PacBio Updates on Impending Revio, Onso Shipments

    Jan 13 | Bio-IT World | In his second J.P. Morgan Healthcare Conference address on behalf of Pacific Biosystems, CEO Christian Henry gave a summary of 2022 numbers and updates on the new sequencing platforms the company announced in October: the Revio long-read platform and the Onso short-read platform. More
  • Why Tech Transfer Needs a New Blueprint

    Jan 13 | Bio-IT World | In BioPharma, development to manufacturing often feel as if they are separated by an invisible wall. While the enterprise may be joint, development and manufacturing cultures are distinct. Poor information sharing can make findings feel like closely guarded secrets. This siloed approach was the accepted norm in earlier eras. Now, it is due for a major renovation. More
  • At J.P. Morgan Illumina Reports Record-Breaking Uptake of NovaSeq X, Expanding Sequencing Market

    Jan 12 | Bio-IT World | Illumina President and CEO Francis deSouza kicked off his annual J.P. Morgan Healthcare Conference presentation highlighting the breadth of the genomics market. deSouza sees a $120 billion total addressable market for Illumina, with oncology testing representing more than half of the opportunity. More
  • Three Pillars of 10x: Outlook for Single Cell, Spatial and In Situ Platforms

    Jan 11 | Bio-IT World | Serge Saxonov, CEO and co-founder of 10x Genomics, kicked off Monday’s sessions at the 41st annual J.P. Morgan Healthcare Conference with an overview of the company’s overall progress in its Visium, Chromium, and Xenium platforms. Instead of delving too deeply in specific product announcements, Saxonov emphasized the strength of the 10x team, the mergers and acquisitions that have led to the development of the platforms, and the breadth of the company offerings. More
View more articles
Bio IT World Lead Gen


Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!